Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Introduction T-cells genetically engineered to express a chimeric antigen receptor (CAR) that targets a specific tumor antigen have become a major clinical tool to treat several high-risk hematologic malignancies. Since the development of the first CAR T-cell in 1989, remarkable…
Background: Natural Killer Cell Biology In 1973, Ivan Roitt's laboratory identified a new class of lymphocytes dubbed “null” killer cells, since they were neither T-cells nor B cells. The following year, these “null” lymphocytes were found to have spontaneous ability…
Introduction The goal of treatment for multiple myeloma, an incurable hematologic malignancy, is to achieve the deepest possible response with the longest duration of remission upfront to achieve a durable disease-free state. The pivotal multicenter trial IFM 90 established the…